论文部分内容阅读
目的探讨妥昔单抗治疗免疫性血小板减少症的效果。方法选择免疫性血小板减少症患者130例,依据利妥昔单抗剂量分为标量组和小量组,每组65例,比较两组治疗效果。结果治疗4周后,小量组的CD8+、CD19+淋巴细胞数、血常规指标改善优于标量组,差异有统计学意义(P<0.05);小量组免疫球蛋白水平优于标量组,差异有统计学意义(P<0.05)。小量组总有效率(76.92%)高于标量组(61.54%),差异有统计学意义(P<0.05)。结论小剂量利妥昔单抗治疗免疫性血小板减少症,不良反应小,安全性高,能改善预后,值得临床推广应用。
Objective To investigate the effect of tocilizumab in the treatment of immune thrombocytopenia. Methods Thirty patients with immune thrombocytopenia were selected and divided into two groups according to the dosage of rituximab: scalar group and small dose group, with 65 cases in each group. The therapeutic effect was compared between the two groups. Results After 4 weeks of treatment, the number of CD8 +, CD19 + lymphocytes and the improvement of blood indexes in small volume group were better than those in the scalar group (P <0.05), and the immunoglobulin level in the small volume group was better than that in the scalar group There was statistical significance (P <0.05). The total effective rate of small group (76.92%) was higher than that of scalar group (61.54%), the difference was statistically significant (P <0.05). Conclusion Low dose rituximab treatment of immune thrombocytopenia, adverse reactions, high safety, can improve the prognosis, it is worthy of clinical application.